Literature DB >> 22836278

Treatment failure in osteoporosis.

A Diez-Perez1, J D Adachi, D Agnusdei, J P Bilezikian, J E Compston, S R Cummings, R Eastell, E F Eriksen, J Gonzalez-Macias, U A Liberman, D A Wahl, E Seeman, J A Kanis, C Cooper.   

Abstract

UNLABELLED: Guidelines concerning the definition of failure of therapies used to reduce the risk of fracture are provided.
INTRODUCTION: This study aims to provide guidelines concerning the definition of failure of therapies used to reduce the risk of fracture.
METHODS: A working group of the Committee of Scientific Advisors of the International Osteoporosis Foundation was convened to define outcome variables that may assist clinicians in decision making.
RESULTS: In the face of limited evidence, failure of treatment may be inferred when two or more incident fractures have occurred during treatment, when serial measurements of bone remodelling markers are not suppressed by anti-resorptive therapy and where bone mineral density continues to decrease.
CONCLUSION: The provision of pragmatic criteria to define failure to respond to treatment provides an unmet clinical need and may stimulate research into an important issue.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836278     DOI: 10.1007/s00198-012-2093-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  41 in total

1.  The burden of osteoporotic fractures: a method for setting intervention thresholds.

Authors:  J A Kanis; A Oden; O Johnell; B Jonsson; C de Laet; A Dawson
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

2.  Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.

Authors:  Nelson B Watts; Piet Geusens; Ian P Barton; Dieter Felsenberg
Journal:  J Bone Miner Res       Date:  2005-08-08       Impact factor: 6.741

3.  Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.

Authors:  P Hadji; D Gamerdinger; W Spieler; P H Kann; H Loeffler; K Articus; R Möricke; V Ziller
Journal:  Osteoporos Int       Date:  2011-03-26       Impact factor: 4.507

4.  Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.

Authors:  Somnath Sarkar; Bruce H Mitlak; Mayme Wong; John L Stock; Dennis M Black; Kristine D Harper
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

5.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

6.  Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

Authors:  R Eastell; I Barton; R A Hannon; A Chines; P Garnero; P D Delmas
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741

7.  Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.

Authors:  J-Y Reginster; S Sarkar; B Zegels; Y Henrotin; O Bruyere; D Agnusdei; J Collette
Journal:  Bone       Date:  2004-02       Impact factor: 4.398

8.  Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses.

Authors:  P D Delmas; Zhengqing Li; Cyrus Cooper
Journal:  J Bone Miner Res       Date:  2003-12-16       Impact factor: 6.741

9.  Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk.

Authors:  Somnath Sarkar; Jean-Yves Reginster; Gerald G Crans; Adolfo Diez-Perez; Karen V Pinette; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2003-12-22       Impact factor: 6.741

10.  Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.

Authors:  Catherine MacLean; Sydne Newberry; Margaret Maglione; Maureen McMahon; Veena Ranganath; Marika Suttorp; Walter Mojica; Martha Timmer; Alicia Alexander; Melissa McNamara; Sheetal B Desai; Annie Zhou; Susan Chen; Jason Carter; Carlo Tringale; Di Valentine; Breanne Johnsen; Jennifer Grossman
Journal:  Ann Intern Med       Date:  2007-12-17       Impact factor: 25.391

View more
  40 in total

1.  Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study.

Authors:  William A Bauman; Christopher M Cirnigliaro; Michael F La Fountaine; LeighAnn Martinez; Steven C Kirshblum; Ann M Spungen
Journal:  J Bone Miner Metab       Date:  2014-08-27       Impact factor: 2.626

2.  Bone diseases. Incident fractures during treatment for osteoporosis.

Authors:  Peter Vestergaard
Journal:  Nat Rev Rheumatol       Date:  2013-08-13       Impact factor: 20.543

Review 3.  [Management of osteoporosis after fragility fractures].

Authors:  M Gosch; U Stumpf; C Kammerlander; W Böcker; H J Heppner; S Wicklein
Journal:  Z Gerontol Geriatr       Date:  2018-01-05       Impact factor: 1.281

4.  Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate.

Authors:  M P Yavropoulou; N A T Hamdy; S E Papapoulos
Journal:  Osteoporos Int       Date:  2013-02-23       Impact factor: 4.507

Review 5.  Bone loss at the distal femur and proximal tibia in persons with spinal cord injury: imaging approaches, risk of fracture, and potential treatment options.

Authors:  C M Cirnigliaro; M J Myslinski; M F La Fountaine; S C Kirshblum; G F Forrest; W A Bauman
Journal:  Osteoporos Int       Date:  2016-12-05       Impact factor: 4.507

6.  International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.

Authors:  A Diez-Perez; K E Naylor; B Abrahamsen; D Agnusdei; M L Brandi; C Cooper; E Dennison; E F Eriksen; D T Gold; N Guañabens; P Hadji; M Hiligsmann; R Horne; R Josse; J A Kanis; B Obermayer-Pietsch; D Prieto-Alhambra; J-Y Reginster; R Rizzoli; S Silverman; M C Zillikens; R Eastell
Journal:  Osteoporos Int       Date:  2017-01-16       Impact factor: 4.507

Review 7.  Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.

Authors:  Pojchong Chotiyarnwong; Eugene V McCloskey
Journal:  Nat Rev Endocrinol       Date:  2020-04-14       Impact factor: 43.330

Review 8.  Treatment of osteoporosis after alendronate or risedronate.

Authors:  P Eiken; P Vestergaard
Journal:  Osteoporos Int       Date:  2015-10-05       Impact factor: 4.507

Review 9.  New strategies for osteoporosis patients previously managed with strontium ranelate.

Authors:  Peter Vestergaard
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-12       Impact factor: 5.346

10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2018-10-15       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.